Physicians treating patients with CAP tend to overestimate or underestimate the prevalence of infections caused by atypical pathogens. Are there any recent data that could be helpful in identifying patients with atypical infection?
Some recently published papers reported changes in the bacterial load in the lungs of patients with idiopathic pulmonary fibrosis. Are there any ongoing trials on antibiotics or other treatments based on these findings?
Full-face masks or helmets are not used universally in everyday practice. What is your experience with using such devices? Do you use them often in your practice? Which patients would benefit most from this type of intervention?
The WHO advocates several regimens for the treatment of latent tuberculosis (TB) infection. Are there any new data comparing different treatments that suggest which regimen would be optimal for adults with rheumatoid arthritis (RA) who have been treated for latent TB infection before starting biologic therapy for RA?
What is your opinion on using nintedanib and pirfenidone in patients with forced vital capacity <50%? Are there any data available to support such treatment?
The use of noninvasive ventilation in asthma exacerbations is often discussed but rarely applied in daily practice. Which patients may benefit from this intervention?
There is a tendency to keep the duration of antibiotic treatment for community-acquired pneumonia as short as possible. Treatment of 5 days is safe and effective but is it associated with an increased risk of selection of resistant pathogens?
What should be the optimal pressures during long-term noninvasive ventilation in patients with chronic obstructive pulmonary disease?
In the European Union, the incidence of drug-resistant tuberculosis TB is low. However, the situation in Russia and former Soviet republics is very concerning. As these countries border Poland and are frequently travelled to and from, should we expect that the incidence of drug-resistant TB may increase in the regions of Poland adjacent to the border?
Do you think procalcitonin has a potential to replace C-reactive protein as the first-line diagnostic study in patients with suspected community-acquired pneumonia?
English
Polski
Español
українська